Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD [0.03%]
奥希替尼耐药T790M阴性C797S阳性的EGFR突变阳性晚期非小细胞肺癌患者中使用奥希替尼联合吉非替尼治疗的疗效：ORCHARD试验
Sarah B Goldberg,Myung-Ju Ahn,Christina Baik et al.
Sarah B Goldberg et al.
Purpose: ORCHARD (NCT03944772) was a phase II, open-label study evaluating resistance mechanisms and post-progression therapies in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung...
Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects [0.03%]
PER3昼夜基因型与前列腺癌放射治疗时间相互作用影响晚期副作用风险
Adam J Webb,Emily Harper,Tim Rattay et al.
Adam J Webb et al.
Purpose: We showed previously that breast cancer patients with certain circadian rhythm genotypes have higher incidences of toxicity when treated with radiotherapy at different times of day. This opens the way to genetica...
Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes [0.03%]
靶向核素治疗：当前格局及联合治疗策略以改善肿瘤预后
Julie Nonnekens,Lauren A Byers,Aman Chauhan et al.
Julie Nonnekens et al.
Targeted radionuclide therapy (TRT) is an emerging modality in oncology that delivers internal radiation specifically to tumor sites. It typically consists of a particle-emitting radionuclide, a linking complex with a chelator for securely ...
The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML [0.03%]
新型低甲基化药物NTX-301重编程表观遗传和Hippo信号通路，并在维奈克拉耐药和TP53突变的急性髓系白血病小鼠模型中表现出临床前活性
Bing Z Carter,Po Yee Mak,Suresh Satpati et al.
Bing Z Carter et al.
Background: Hypomethylating agent (HMA) and the BCL-2 inhibitor venetoclax (VEN) combinations have evolved into frontline therapies for patients with acute myeloid leukemia (AML), yielding high response rates. However, mo...
Komal Gupta,Daniel S W Tan,Regina Hoo
Komal Gupta
A recent article presents the largest histo-genomic characterisation of first-line osimertinib resistance from ORCHARD study. Dual-modality tissue and plasma sequencing detected resistance alterations in 87% and polyclonal mechanisms in 46%...
Maxwell R Lloyd,Mark D Pegram,Seth A Wander
Maxwell R Lloyd
HER2-directed tyrosine kinase inhibitor combinations with trastuzumab represent an emerging strategy for hormone receptor-negative or -positive metastatic breast cancer with activating HER2 mutations. Correlative genomics reveal on-target a...
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer [0.03%]
MTAP缺失型晚期非小细胞肺癌患者的临床特征及系统治疗预后分析
Julian Huang,Mihaela Aldea,Kathryn W Miller et al.
Julian Huang et al.
Purpose: Methylthioadenosine phosphorylase (MTAP) is deleted in 13% of NSCLC, and MTAP two-copy deleted (MTAPdel) cancer cells are vulnerable to protein arginine methyltransferase 5 inhibitors being examined in trials. Ou...
Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer [0.03%]
用于监测复发性膀胱癌的多重尿液生物标志物检测的临床验证
Yair Lotan,Michael Luu,Menghan Liu et al.
Yair Lotan et al.
Background: More than 50% of patients with non-muscle invasive bladder cancer (NMIBC) experience recurrence, requiring lifelong surveillance with repeated cystoscopy. Given the invasive nature and cost of cystoscopy, accu...
Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma [0.03%]
表观遗传液体活检可对高危神经母细胞瘤进行通用的分子监测
Nurit Gal-Mark,Assaf Grunwald,Valid Gahramanov et al.
Nurit Gal-Mark et al.
Purpose: Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework en...
Mina Nikanjam,Judith Pérez-Granado,Mark W Gramling et al.
Mina Nikanjam et al.
Claudin 18.2 (CLDN18.2) is exclusively expressed on gastric mucosal cell tight junctions with minimal expression in other healthy adult tissues. Prior studies assessed expression by immunohistochemistry, mainly membrane staining. The FDA CL...